Par reaches settlement with Sanofi-Aventis for Eloxatin generic

Alaric DeArment

4/5/2010

WOODCLIFF LAKE, N.J. Par Pharmaceuticals has reached a settlement with Sanofi-Aventis in a case concerning a generic cancer drug, Par announced Monday.

Par said it settled patent litigation with Sanofi over its version of Sanofi’s and Debiopharm’s injectable colorectal cancer drug Eloxatin (oxaliplatin).

Under the agreement, Par can begin selling its version of Eloxatin in August 2012. The drug had sales of $993 million in 2009, according to IMS Health.

Betty Crocker debuts afternoon tea kits inspired by Netflix’s 'Bridgerton'

Betty Crocker collaborated with Netflix's “Bridgerton” to launch baking kits that include crème puffs, sponge cakes and scones.

Coffee mate intros creamers inspired by latest season of ‘The White Lotus’

The two limited-edition creamers include The White Lotus Thai Iced Coffee Flavored Creamer and The White Lotus Pina Colada Flavored Creamer.

BJ’s Wholesale Club opening Maryville, Tenn. store

The club, located at 101 Foothills Mall Drive, is BJ’s fourth club in Tennessee.

Justice Department files nationwide lawsuit against Walgreens

The lawsuit alleges Walgreens knowingly filled millions of prescriptions that lacked a legitimate medical purpose.

Walgreens buyout talks reportedly unlikely to culminate in a deal

A Wall Street Journal report noted that according to CNBC's David Faber, a prospective deal between Walgreens and New York private-equity firm Sycamore Partners is “mostly dead.”